Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Objective: An expert panel convened to reach a consensus on common misconceptions surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for chronic pain. The panel also provided clinical recommendations on the appropriate use of buprenorphine and conversion strategies for switching to buprenorphine from a full µ-opioid receptor agonist for chronic pain management. Methods: The consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorphine as a partial µ-opioid receptor agonist, prescribing buprenorphine before some Schedule II, III, or IV options, perioperative/trauma management of patients taking buprenorphine, and converting patients from a full µ-opioid receptor agonist to buprenorphine. Results: The panel recommended that buprenorphine’s classification as a partial µ-opioid receptor agonist not be clinically translated to mean partial analgesic efficacy. The panel also recommended that buprenorphine be considered before some Schedule II, III, or IV opioids in patients with a favorable risk/benefit profile on the basis of metabolic factors, abuse potential, and tolerability and that buprenorphine be continued during the perioperative/trauma period. In addition, switching patients from a full µ-opioid receptor agonist to buprenorphine should be considered with no weaning period at starting doses that are based on the previous opioid dose. Conclusions: These recommendations provide a framework for clinicians to address most clinical scenarios regarding buprenorphine use. The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The history of buprenorphine. Buprenorphine was originally developed as an analgesic and was subsequently used for OUD before novel delivery systems allowed for approval in chronic pain management [8,9,12,13]. FDA=Food and Drug Administration; OUD=opioid use disorder.](https://figures.cochat.ai/paper-figures/58cc0d7e0c974ec28f2b0cc30c34f79a/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-1.jpg)
![Figure 2 Receptor/ligand definitions and applications to buprenorphine at the μ-opioid receptor. *Definition of a partial agonist: a compound with an intermediate intrinsic activity that at full receptor saturation produces less than the maximal effect obtainable with full agonists in some specified set of in vitro or clinical circumstances [25]. Buprenorphine is a potent Schedule III opioid with high binding affinity at the μ-opioid receptor that behaves as a partial agonist on the basis of in vitro studies [7,14,26]. Although buprenorphine has less total intrinsic activity (capacity to activate a receptor to induce multiple signaling pathways) than full μ-opioid receptor agonists, it still effectively stimulates the analgesic signaling pathway from the μ-opioid receptor [7,14,25,27,28]. 3D=three-dimensional; OR=opioid receptor.](https://figures.cochat.ai/paper-figures/70555884c62b4bf48113c2321c3df2a7/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-2.jpg)
![Figure 3 Efficacy and tolerability of buprenorphine compared with those of other opioids used for chronic pain. (A) Potential mechanism of action for buprenorphine and (B) conceptual representation of possible effects compared with those of Schedule II opioids such as, but not limited to, fentanyl [33,38,39]. OR=opioid receptor; ORL1=opioid receptor-like 1.](https://figures.cochat.ai/paper-figures/fe01b988dfd948c9948091ab1e0785a9/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
Dahlhamer, J., Lucas, J., Zelaya, Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6736a2 · Cited by 2,598
Consensus development methods, and their use in clinical guideline development.
Murphy, Black, Lamping, McKee, Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,051
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Webster, L. R., & Webster, R. M. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00072.x · Cited by 1,096 · cited 1×
“, indications of OUD or substance use disorder, heightened risk of overdose, elevated Opioid Risk Tool [ORT] or other screening tool score [68]) may benefit from buprenorphine [69].”
BackgroundSelf-citationA review of chronic pain impact on patients, their social environment and the health care system
Duenas, M., Ojeda, B., Salazar, A., Mico, J. A., & Failde, I. (2016) · Journal of Pain Research · doi:10.2147/jpr.s105892 · Cited by 985
Consensus development methods, and their use in clinical guideline development.
Murphy, M. P., Black, N. A., Lamping, D. L., et al. (1998) · PubMed · Cited by 965
Opioids and the control of respiration
Pattinson, K. T. S. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen094 · Cited by 793
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Opioids and the treatment of chronic pain: Controversies, current status, and future directions.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 643
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002396 · Cited by 524
Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446 · cited 1×
“Consensus Statement Buprenorphine has higher binding affinity [44] but lower intrinsic activity at the m-opioid receptor than full m-opioid receptor agonists [14], with a unique mechanism of action at other receptors (e.”
BackgroundPratt, V. M., Scott, S. A., Pirmohamed, M., Esquivel, B., Kane, M. S., Kattman, B. L., & Malheiro, A. (2012) · Cited by 414
Buprenorphine induces ceiling in respiratory depression but not in analgesia
Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006) · British Journal of Anaesthesia · doi:10.1093/bja/ael051 · Cited by 376
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356 · cited 1×
“As a caveat, respiratory depression is still a concern, especially when buprenorphine is used in combination with nonopioid sedatives/anticonvulsants such as benzodiazepines and gabapentin [57,58], carisoprodol and other muscle relaxants [59], amitriptyline [60], and Z-drugs (nonbenzodiazepine drugs with effects simil…”
BackgroundComparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats
Dahan, A., Yassen, A., Bijl, H., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei145 · Cited by 326
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320
McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066613 · Cited by 262
Opioid Induced Hyperalgesia: Clinical Implications for the Pain Practitioner
Silverman, S. M. (2009) · Pain Physician · doi:10.36076/ppj.2009/12/679 · Cited by 238
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236
Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model
Koppert, W., Ihmsen, H., Körber, N., Wehrfritz, A., Sittl, R., Schmelz, M., & Schüttler, J. (2005) · Pain · doi:10.1016/j.pain.2005.06.030 · Cited by 227
Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
Pillarisetti, S., & Khanna, I. (2015) · Journal of Pain Research · doi:10.2147/jpr.s85951 · Cited by 195
Modulation of Peripheral Sensory Neurons by the Immune System: Implications for Pain Therapy
Stein, C., & Machelska, H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003145 · Cited by 181
Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain
Davis, M. P. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.05.002 · Cited by 179
Pregabalin and the Risk for Opioid-Related Death: A Nested Case–Control Study
Gomes, T., Greaves, S., van den Brink, W., Antoniou, T., Mamdani, M. M., Paterson, J. M., Martins, D., & Juurlink, D. N. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1136 · Cited by 165
Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162 · cited 1×
“In fact, buprenorphine has been shown to effectively reduce depressive symptoms and suicidal ideation in patients unresponsive to conventional antidepressant medications [37].”
BackgroundZedler, B., Xie, L., Wang, L., Joyce, A., Vick, C., Brigham, J., Kariburyo, F., Baser, O., & Murrelle, L. (2015) · Pain Medicine · doi:10.1111/pme.12777 · Cited by 138
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
The history of the development of buprenorphine as an addiction therapeutic
CAMPBELL, N. D., & Lovell, A. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06352.x · Cited by 135
Naloxone Reversal of Buprenorphine-induced Respiratory Depression
van Dorp, E., Yassen, A., Sarton, E., Romberg, R., Olofsen, E., Teppema, L., Danhof, M., & Dahan, A. (2006) · Anesthesiology · doi:10.1097/00000542-200607000-00012 · Cited by 129
GORDON, A. S., Callaghan, D. J. G., Spink, D., Cloutier, C., Dzongowski, P., O’Mahony, W. F., Sinclair, D., Rashiq, S., Buckley, N., & Cohen, G. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.018 · Cited by 126
Qi, J. N., Mosberg, H. I., & Porreca, F. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12740-7 · Cited by 116
Consensus development for healthcare professionals
Kea, B., & Sun, B. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1156-6 · Cited by 111
Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management
Lintzeris, N., & Nielsen, S. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00007.x · Cited by 110
The clinical analgesic efficacy of buprenorphine
Raffa, R. B., Haidery, M., Huang, H.-M., Kalladeen, K., Lockstein, D. E., Ono, H., Shope, M. J., Sowunmi, O. A., Tran, J. K., & Pergolizzi, J. V. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12196 · Cited by 105
Self-citationMacintyre, P. E., Russell, R., Usher, K. A. N., Gaughwin, M. D., & Huxtable, C. A. (2013) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1304100212 · Cited by 105
Rosado, J., WALSH, S. L., Bigelow, G. E., & Strain, E. C. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.04.006 · Cited by 101
Harrison, T. K., Kornfeld, H., Aggarwal, A. K., & Lembke, A. (2018) · Anesthesiology Clinics · doi:10.1016/j.anclin.2018.04.002 · Cited by 99
Quality of Life Associated with Daily Opioid Therapy in a Primary Care Chronic Pain Sample
Dillie, K. S., Fleming, M. F., Mundt, M. P., & French, M. T. (2008) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2008.02.070144 · Cited by 86
Opioids, respiratory depression, and sleep-disordered breathing
Nagappa, M., Weingarten, T. N., Montandon, G., Šprung, J., & Chung, F. F. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.05.004 · Cited by 82
Traynor, J. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.027 · Cited by 81
Aiyer, R., Gulati, A., Güngör, S., Bhatia, A., & Mehta, N. D. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002718 · Cited by 74
Meske, D. S., Lawal, O. D., Elder, H., Langberg, V., Paillard, F., & Katz, N. P. (2018) · Journal of Pain Research · doi:10.2147/jpr.s160255 · Cited by 72
Some new insights into the effects of opioids in phasic and tonic nociceptive tests
McCormack, K., Prather, P., & Chapleo, C. (1998) · Pain · doi:10.1016/s0304-3959(98)00146-8 · Cited by 70
Buchwald, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00605 · Cited by 69
The Pharmacology and Toxicology of the ‘Holy Trinity’
Horsfall, J. T., & Sprague, J. E. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12655 · Cited by 68
Six Deaths Linked to Misuse of Buprenorphine-Benzodiazepine Combinations
Reynaud, M., Tracqui, A., Petit, G., Potard, D., & Courty, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.447-b · Cited by 68
Dirig, D. M., & Yaksh, T. L. (1995) · Pain · doi:10.1016/0304-3959(95)00006-e · Cited by 67
Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
Zaveri, N. T., Polgar, W. E., Olsen, C. M., Kelson, A. B., Grundt, P., Lewis, J. W., & Toll, L. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01282-1 · Cited by 65
Ding, Z., & Raffa, R. B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00209.x · Cited by 61
Self-citationNadpara, P. A., Joyce, A. R., Murrelle, E. L., Carroll, N. W., Carroll, N. V., Barnard, M., & Zedler, B. K. (2017) · Pain Medicine · doi:10.1093/pm/pnx038 · Cited by 58
Intrinsic Activity: Partial Agonists and Partial Antagonists
Ariëns, E. J. (1983) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198300051-00002 · Cited by 57
Leighton, B. L., & Crock, L. W. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002498 · Cited by 51
Yamamoto, T., Shono, K., & Tanabe, S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100859 · Cited by 48
Ahmadi, J., Jahromi, M. S., & Ehsaei, Z. (2018) · Trials · doi:10.1186/s13063-018-2843-9 · Cited by 48 · cited 1×
“Buprenorphine is a full agonist at the more recently identified opioid receptor-like 1 (ORL1), which may contribute to analgesia [34], and it is an antagonist at the dand j-opioid receptors, which lessen constipation, dysphoria, and abuse potential and help reduce mental depression [7,35,36].”
BackgroundSaarialho‐Kere, U., Mattila, M. J., Paloheimo, M., & Sepp�l�, T. (1987) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544557 · Cited by 48
Kornfeld, H., & Reetz, H. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828bfb6e · Cited by 45
Payandemehr, P., Jalili, M., Davani, B. M., & Dehpour, A. R. (2014) · International Journal of Emergency Medicine · doi:10.1186/1865-1380-7-1 · Cited by 42
Weighing the Risks and Benefits of Chronic Opioid Therapy.
Lembke, A., Humphreys, K. N., & Newmark, J. L. (2016) · PubMed · Cited by 42
Raffa, R. B., & Ding, Z. (2007) · Acute Pain · doi:10.1016/j.acpain.2007.07.002 · Cited by 40
Self-citationCodeine Therapy and CYP2D6 Genotype
Dean, L. (2016) · Europe PMC (PubMed Central) · Cited by 35
In vivo potency revisited – Keep the target in sight
Gabrielsson, J., Peletier, L. A., & Hjorth, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.011 · Cited by 35
Buprenorphine Therapy of Opiate Addiction
Kintz, P., & Marquet, P. (2002) · Humana Press eBooks · doi:10.1385/1592592821 · Cited by 34
Sittl, R., Nuijten, M. J. C., & Nautrup, B. P. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.024 · Cited by 33
Induction of patients with moderately severe methadone dependence onto buprenorphine
Glasper, A., Reed, L., de Wet, C., Gossop, M., & Bearn, J. (2005) · Addiction Biology · doi:10.1080/13556210500123126 · Cited by 27
COPLAN, P. M., Sessler, N. E., Harikrishnan, V., Singh, R., & Perkel, C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1269596 · Cited by 27
Streltzer, J., Davidson, R., & Goebert, D. (2015) · The American Journal on Addictions · doi:10.1111/ajad.12198 · Cited by 16
Zebala, J. A., Searle, S. L., Webster, L. R., Johnson, M. S., Schuler, A. D., Maeda, D. Y., & Kahn, S. J. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.04.005 · Cited by 16
Self-citationControlled Drug Administration Studies of High-Dose Buprenorphine in Humans
Huestis, M. A. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-282-1_2 · Cited by 6
Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans
Huestis, M. A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-282-1:13 · Cited by 2
痛みのあるか,痛みないか? 感覚と痛みの評価尺度は実験的文脈において良くなる【JST・京大機械翻訳】
Victoria, J. M., Peter, R., Bellan, V., Mark, J. C., Leslie, N. R., Camfferman, D., & Moseley, G. L. (2019) · Journal of Pain · Cited by 1
Research works printed but not linked: 2
- 10. Belbuca [Prescribing Information]. Raleigh, NC: BioDelivery Sciences International, Inc; 2018.
- 11. Butrans [Prescribing Information]. Stamford, CT: Purdue Pharma L.P; 2018.
Cited by
Lagisetty, P., Garpestad, C., Larkin, A., Macleod, C., Antoku, D., Slat, S., Thomas, J., Powell, V. D., Bohnert, A. S. B., & Lin, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108583 · Cited by 112
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
Spreen, L. A., Dittmar, E. N., Quirk, K. C., & Smith, M. A. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2676 · Cited by 85
Buprenorphine and its formulations: a comprehensive review
Poliwoda, S., Noor, N., Jenkins, J. S., Stark, C. W., Steib, M., Hasoon, J. J., Varrassi, G., Urits, I., Viswanath, O., Kaye, A. M., et al. (2022) · Health Psychology Research · doi:10.52965/001c.37517 · Cited by 80
Pharmacological Pain Treatment in Older Persons
Pickering, G. P., Kotlińska–Lemieszek, A., Škvarč, N. K., O’Mahony, D., Monacelli, F., Knaggs, R., Morel, V., & Kocot-Kępska, M. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01151-8 · Cited by 67
Jones, K. F., Khodyakov, D., Arnold, R. M., Bulls, H. W., Dao, E., Kapo, J. M., Meier, D. E., Paice, J. A., Liebschutz, J. M., Ritchie, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2191 · Cited by 59
Metadata
- Authors
- Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T.
- Affiliations
- PRA Health Sciences (US)
- Englewood Hospital and Medical Center (US)
- University of Arizona (US)
- Cassava Sciences (United States) (US)
- Carolinas Pain Institute (US)
- Western New England University (US)
- Pacific Pain Medicine Consultants, Encinitas, California
- Division of Pain Medicine, Stanford Medicine Outpatient Center, Redwood City, California, USA
- Corresponding author
- Webster, Lynn
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-09
- Volume
- 21
- Issue
- 4
- Pages
- 714-723
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- PMC
- PMC7139205
- OpenAlex
- W2999420193
- Semantic Scholar
- cc2517b813031b59a622a7fb6090710466afcf83
- Cited by
- 130
- References
- 70
- Citations by year
- 2026: 13 · 2025: 35 · 2024: 20 · 2023: 24 · 2022: 18 · 2021: 14 · 2020: 6
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Pain Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- BioDelivery Sciences International, Inc.
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- buprenorphine, chronic pain management, opioid conversion, opioid prescribing, perioperative care, trauma management, opioid abuse potential, analgesic efficacy
- MeSH terms
- Analgesics, Opioid, Buprenorphine, Humans, Practice Guidelines as Topic, Receptors, Opioid, mu, Drug Substitution, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.